ClinicalTrials.gg
Status unknownNCT03330873Updated Nov 6, 2017

The Efficacy and Safety of Disposable Balloon Uterine Stent in Patients With Asherman Syndrome

An interventional study of disposable balloon uterine stent and Foley catheter in Intrauterine Adhesion, sponsored by Beijing Obstetrics and Gynecology Hospital. Status unknown at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by Beijing Obstetrics and Gynecology Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Asherman's syndrome is characterized by the presence of intrauterine adhesions (IUA) as well as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility. The gold standard for the treatment of intrauterine adhesions is hysteroscopic intrauterine adhesions. The recurrence of intrauterine adhesions is a major challenge in clinical practice. The isolation of barriers in the uterine cavity may be a measure to reduce postoperative re adhesion, but the effect of different devices is different. Therefore, this study was conducted.

Read the detailed description

The Foley catheter is usually inserted into the uterine after a hysteroscopic adhesiolysis and removed after on the 5-7th day after surgery. Several investigators demonstrated its favorable effect in the recurrence of adhesion after the treatment of intrauterine adhesion. Disposable balloon uterine stent is specially designed to fit into the cavity of the uterus, and usually removed on the 7th day after surgery.

02

Conditions studied

  • Intrauterine Adhesion

Browse trials for

Keywords

  • Asherman syndrome
  • disposable balloon uterine stent
  • hysteroscopy
  • Foley catheter
03

In context

Gynatresia

99 studies on the registry are indexed under Gynatresia; 23 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 87 interventional studies indexed under Gynatresia.

Browse Gynatresia studies →

Lead sponsor

Beijing Obstetrics and Gynecology Hospital is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 20-40 years;
  • Moderate to severe intrauterine adhesion (AFS score ≥5);
  • complains of menstruation disorder and reproductive dysfunction
  • Agreement to have second-look hysteroscopy

Exclusion criteria

Exclusion Criteria:

  • ovarian failure
  • patients who did not proceed to second-look hysteroscopy within the specified time frame
  • of hormone
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Foley catheter

    After the completion of hysteroscopic adhesiolysis, Foley catheter was inserted and inflated with normal saline which was removed on the 7th day after surgery.

    Device: Foley catheter

  • Experimental
    Disposable balloon uterine stent

    After the completion of hysteroscopic adhesiolysis, disposable balloon uterine stent was inserted and inflated with normal saline which was removed on the 7th day after surgery.

    Device: disposable balloon uterine stent

Interventions

  • Devicedisposable balloon uterine stent

    The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter

  • DeviceFoley catheter

    Foley catheter can partly separate the sides of uterus wall.

06

What researchers measure

Primary outcomes

  1. second diagnostic hysteroscopy

    AFS score(The American Fertility Society classifications)

    Time frame: Within the first 3 months after surgery

Secondary outcomes

  1. Menstruation Pattern

    Improvement or No Significant Change

    Time frame: Within the first 3 months after surgery

  2. Number of participants with pregnancy

    Number of biochemical pregnancies and clinical pregnancies

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
  • Beijing Obstetrics and Gynecology Hospital,Capital Medical University
    Beijing, Beijing 100006, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03330873
Lead sponsor
Beijing Obstetrics and Gynecology Hospital
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Oct 23, 2017
Primary completion
Aug 20, 2018 (estimated)
Completion
Oct 20, 2018 (estimated)
Last update
Nov 6, 2017

Study contacts

Zhu Ru, MD
Contact
zhuru19790202@163.com
+8613966636438
Wang Sha, MD
Contact
wangsha1020@163.com
+8615201556908
Duan Hua, PhD
study chair · Beijing Obstetrics and Gynecology Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion